Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

<p>Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Roberto Carmagnani Pestana (15294422) (author)
Бусад зохиолчид:	Justin T. Moyers (15047706) (author), Jason Roszik (15017091) (author), Shiraj Sen (15294425) (author), David S. Hong (15019257) (author), Aung Naing (15023555) (author), Cynthia E. Herzog (15012524) (author), Siqing Fu (15047712) (author), Sarina A. Piha-Paul (15294428) (author), Jordi Rodon (15047721) (author), Timothy A. Yap (15028749) (author), Daniel D. Karp (15294431) (author), Apostolia M. Tsimberidou (15294434) (author), Shubham Pant (15122815) (author), Maria A. Zarzour (15294437) (author), Ravin Ratan (15044195) (author), Vinod Ravi (15047730) (author), Robert S. Benjamin (15012521) (author), Alexander J. Lazar (14963562) (author), Wei-Lien Wang (15294440) (author), Najat Daw (15294443) (author), Jonathan B. Gill (15086581) (author), Douglas J. Harrison (15294446) (author), Valerae O. Lewis (15294449) (author), Christina L. Roland (15294452) (author), Shreyaskumar R. Patel (15062448) (author), J. Andrew Livingston (15294455) (author), Neeta Somaiah (14963553) (author), Joseph A. Ludwig (15016911) (author), Anthony P. Conley (15294458) (author), Nelson Hamerschlak (15294461) (author), Richard Gorlick (15019631) (author), Funda Meric-Bernstam (10258780) (author), Vivek Subbiah (8737068) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Drug Targets Precision Medicine Sarcomas
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

SPIRIT schedule of enrollment, interventions, and assessment.
-н: Kim Christin Honselmann (21176936)
Хэвлэсэн: (2025)

Participant timeline: Schedule of enrollment, interventions, and assessments.
-н: Pierre Angelvy (22683450)
Хэвлэсэн: (2025)

A table showing the clinical participants who were enrolled in a further or higher education course and their research activity and self-declared involvement.
-н: Zoe Edwards (3823528)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
-н: James S. Wilmott (15008931)
Хэвлэсэн: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
-н: James S. Wilmott (15008931)
Хэвлэсэн: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
-н: Iris van 't Erve (15054503)
Хэвлэсэн: (2025)

Serum neuregulin -1 (NRG-1) is a potential biomarker for early diagnosis and prediction in refractory schizophrenia
-н: Ming Shu (22683656)
Хэвлэсэн: (2025)

Figure 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
-н: Marianna Carrabotta (8193039)
Хэвлэсэн: (2025)

Figure 2 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
-н: Marianna Carrabotta (8193039)
Хэвлэсэн: (2025)

Figure 3 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
-н: Marianna Carrabotta (8193039)
Хэвлэсэн: (2025)

Figure 4 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
-н: Marianna Carrabotta (8193039)
Хэвлэсэн: (2025)

Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
-н: Marianna Carrabotta (8193039)
Хэвлэсэн: (2025)

Table 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
-н: Marianna Carrabotta (8193039)
Хэвлэсэн: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
-н: Sebastian Johannes Schober (14971891)
Хэвлэсэн: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
-н: Milana A. Bergamino (15038015)
Хэвлэсэн: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
-н: Milana A. Bergamino (15038015)
Хэвлэсэн: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
-н: Milana A. Bergamino (15038015)
Хэвлэсэн: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
-н: Milana A. Bergamino (15038015)
Хэвлэсэн: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
-н: Milana A. Bergamino (15038015)
Хэвлэсэн: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
-н: Milana A. Bergamino (15038015)
Хэвлэсэн: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
-н: David Olayinka Kamson (16617218)
Хэвлэсэн: (2025)

Supplementary Table 2 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
-н: David Olayinka Kamson (16617218)
Хэвлэсэн: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Table S1. Isometric handgrip force-matched participant demographics and LV morphology.
-н: Corey Tomczak (22648301)
Хэвлэсэн: (2025)

Data_Sheet_1_Benchmarking quantum annealing with maximum cardinality matching problems.PDF
-н: Daniel Vert (18769933)
Хэвлэсэн: (2025)

<b>Figure S1.</b><b> Cardiac MRI LV volume responses to EX and MMA in</b><b> </b><b>i</b><b>sometric handgrip force-matched-matched males and females</b>
-н: Corey Tomczak (22648301)
Хэвлэсэн: (2025)

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
-н: Benjamin K. Wilke (15055112)
Хэвлэсэн: (2025)

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
-н: Benjamin K. Wilke (15055112)
Хэвлэсэн: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_f7mtsv4viojpk7jmnkjg3g7hmh